LK
Louise Frederika Kooij
Chief Accounting Officer

Louise Frederika Kooij insider trades: NewAmsterdam Pharma (NAMS) stock sales

Chief Accounting Officer, NewAmsterdam Pharma Last trade Jul 20, 2026 16 Form 4 filings
$11.6M
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Louise reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 20, 2026NAMS↓ Sell$3.2M
Jun 22, 2026NAMS↓ Sell$1.2M
May 26, 2026NAMS↓ Sell$2.3M
Jan 28, 2026NAMS↓ Sell$2.3M
Jan 26, 2026NAMS↓ Sell$2.4M
Jan 5, 2026NAMS↓ Sell$88K
Sep 9, 2025NAMS↓ Sell$3.9M
Sep 3, 2025NAMS↓ Sell$453K
Aug 25, 2025NAMS↓ Sell$206K
Mar 4, 2025NAMS↓ Sell$3.1M
Oct 1, 2024NAMS↓ Sell$707K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NAMS insiders

Open-market trades in the last 12 months

About Louise Frederika Kooij's insider trades

Louise Frederika Kooij is Chief Accounting Officer at NewAmsterdam Pharma (NAMS). Since Oct 1, 2024, Louise has reported no open-market purchases and 11 sales worth $19.8M on SEC Form 4. In the last 12 months: 6 sales ($11.6M).

Their filings also include option exercises (10 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NAMS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.